Sotorasib is a first-generation targeted drug

Sotorasib (Sotorasib) is the first-generation KRAS G12C mutation-targeting drug. Currently, targeted drugs targeting the KRAS G12C mutation are still in a relatively early stage. Sotoraxib is the most representative of these, but there are other similar drugs being developed and evaluated. Sotorasiib acts specifically on the KRAS G12C mutant protein, inhibits its activity, and blocks abnormal signal transduction pathways. This helps reduce the ability of cancer cells to proliferate and grow, thereby inhibiting tumor development.

With the continuous progress of scientific research, new and more efficient second-generation or subsequent generations of KRAS G12C-targeted drugs may emerge. These drugs may have better efficacy and tolerability and provide patients with more treatment options. Sotorasiib has been authorized by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced or metastatic NSCLC harboring the KRAS G12C mutation. It is considered a promising targeted therapy, providing a new treatment option for patients who cannot undergo surgery or radiotherapy. .

SotoracibThe original drug has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. The price of Hong Kong original research versionsotorasibuSpecifications120mg*240 tablets is about RMB 80,000, and the European original research version 120mg*240 tablets is priced at about RMB 44,040 (the price may fluctuate due to the exchange rate), which is relatively expensive. There are also cheaper generic drugs for sale in other countries. The specifications of the Laos Element Pharmaceutical Factory are 120mg*56 tablets and the price is around 4800 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of foreign generic drugs are basically the same as the original drugs.